Clinical Trial Detail

NCT ID NCT02605967
Title Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

nasopharynx carcinoma

Therapies

Spartalizumab

Age Groups: adult

No variant requirements are available.